Teplizumab awarded innovation passport in the united kingdom (uk) for the delay of onset of clinical type 1 diabetes in at-risk individuals

Red bank, n.j., july 12, 2021 /prnewswire/ -- provention bio, inc. (nasdaq: prvb), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that teplizumab, an anti-cd3 monoclonal antibody (mab), was awarded an innovation passport for the delay of clinical type 1 diabetes (t1d) in at-risk individuals.
PRVB Ratings Summary
PRVB Quant Ranking